Experienced in Autoimmune Hemolytic Anemia

Dr. Vinod A. Pullarkat

City Of Hope Medical Foundation
South Pasadena, CA
Experienced
in Autoimmune Hemolytic Anemia
Specialties:Hematology | Hematology Oncology
OverviewInsuranceLocationsClinical Research

Overview

Vinod Pullarkat is a Hematologist and a Hematologist Oncology provider in South Pasadena, California. Mr. Pullarkat and is rated as an Experienced provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 185 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030
626-396-2900
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
626-256-4673

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drugs: Sabatolimab, Azacitidine, Venetoclax
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Other, Drug
Study Drug: 8-Chloroadenosine
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Biological
Study Drugs: Thrombosomes, Liquid-Stored Platelets
Study Phase: Phase 2
View 5 Less Clinical Trials

186 Total Publications

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 17, 2024
Similar Doctors
Expertise in
40
conditions
Dr. Ilene C. Weitz
Hematology
Expertise in
40
conditions
Dr. Ilene C. Weitz
Hematology

USC Care Medical Group Inc

1441 Eastlake Ave, 
Los Angeles, CA 
 (5.3 mi)
323-865-3000
Languages Spoken:
English
See accepted insurances

Ilene Weitz is a Hematologist in Los Angeles, California. Dr. Weitz and is rated as an Elite provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Autoimmune Hemolytic Anemia, Hemolytic Anemia, Splenectomy, and Bone Marrow Aspiration.

Expertise in
26
conditions
Dr. Caroline I. Piatek
Hematology | Oncology
Expertise in
26
conditions
Dr. Caroline I. Piatek
Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (5.1 mi)
800-872-2273
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Caroline Piatek is a Hematologist and an Oncologist in Los Angeles, California. Dr. Piatek has been practicing medicine for over 16 years and is rated as an Elite provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Splenectomy, and Bone Marrow Aspiration.

Expertise in
70
conditions
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology
Expertise in
70
conditions
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (5.1 mi)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Casey O'connell is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. O'connell and is rated as an Elite provider by MediFind in the treatment of Autoimmune Hemolytic Anemia. Her top areas of expertise are Polycythemia Vera, Myelodysplastic Syndrome (MDS), Myelofibrosis, Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile